Immunic Therapeutics

IN THE PRESS

Policy

Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts

November 2, 2023

·

7 min read

Pharm Country

Immunic to Participate in Scientific and Industry Conferences in November 2023

October 26, 2023

·

5 min read

Drug Development

Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023

October 16, 2023

·

7 min read

Drug Development

Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023

October 15, 2023

·

7 min read

Drug Development

Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting

October 11, 2023

·

8 min read

Drug Development

Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

October 9, 2023

·

12 min read

Pharm Country

Immunic to Participate in Scientific Conferences in October 2023

October 4, 2023

·

6 min read

JOBS